You searched for Acalabrutinib - Page 5 of 25

ASH 2020: Dr. Paolo Ghia Discusses the ASCEND Study – Acalabrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia or CLL

March 1, 2021

During ASH 2020, Dr. Paolo Ghia discussed the ASCEND Study – Acalabrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in Relapsed or Refractory CLL. Dr. Ghia presented the final analyses of the ASCEND trial after nearly two years of follow-up. Acalabrutinib was the clear winner.

ASH 2020: Dr. Jennifer Brown on Cardiovascular Events in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib

February 8, 2021

ASH 2020: Dr. Jennifer Brown on cardiovascular events in patients with chronic lymphocytic leukemia (CLL) treated with acalabrutinib

Update on CALAVI Phase II Trials for Acalabrutinib in Patients Hospitalized with Respiratory Symptoms of COVID-19

January 4, 2021

There has been much excitement about the possibility that BTK inhibitors such as ibrutinib or acalabrutinib might improve outcomes in COVID-19 for all patients ever since Dr. Treon published a retrospective

ASCO 2020 “Top 12” #2: Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability

August 20, 2020

#2 At virtual ASCO 2020, Dr. John Byrd led a group of researchers to report the latest from the first phase 2 study of acalabrutinib, ACE-CL-001 (NCT02029443), a next-generation BTK inhibitor, which is now approved for CLL patients, both treatment-naïve as well as those with relapsed/refractory disease.

ASH 2019: Dr Deborah Stephens on ARQ 531, a reversible BTK inhibitor to treat CLL that is no longer responding to ibrutinib or acalabrutinib, and maybe more.

June 15, 2020

ASH 2019: Dr Deborah Stephens on ARQ 531, a reversible BTK inhibitor to treat CLL that is no longer responding to ibrutinib or acalabrutinib, and maybe more.

Things to Know About Acalabrutinib

March 20, 2020

Getting a laboratory test result really has no meaning without having something with which to compare it. Its meaning comes from comparing it to reference values, which are the values expected for a group of otherwise healthy persons.

ASCO 2019: Dr. Koffman’s Pick #3 Acalabrutinib in ibrutinib-intolerant relapsed/refractory chronic lymphocytic leukemia (CLL)

December 22, 2019

Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of the CLL Society, counts down his top ten CLL related abstract from ASCO or the American Society

ASCO 2019: Dr. Koffman’s Pick #6: Acalabrutinib with Obinutuzumab for chronic lymphocytic leukemia (CLL)

December 16, 2019

Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of the CLL Society, counts down his top ten CLL related abstract from ASCO or the American Society

U.S. Food and Drug Administration (FDA) Approves Acalabrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)

November 21, 2019

For immediate release, Nov 21. 2019 U.S. Food and Drug Administration (FDA) Approves Acalabrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL) On November 21, 2019, the FDA announced that it had

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: Acalabrutinib – Page 5

ASH 2020: Dr. Paolo Ghia Discusses the ASCEND Study – Acalabrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia or CLL

ASH 2020: Dr. Jennifer Brown on Cardiovascular Events in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib

Update on CALAVI Phase II Trials for Acalabrutinib in Patients Hospitalized with Respiratory Symptoms of COVID-19

ASCO 2020 “Top 12” #2: Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability

ASH 2019: Dr Deborah Stephens on ARQ 531, a reversible BTK inhibitor to treat CLL that is no longer responding to ibrutinib or acalabrutinib, and maybe more.

Things to Know About Acalabrutinib

ASCO 2019: Dr. Koffman’s Pick #3 Acalabrutinib in ibrutinib-intolerant relapsed/refractory chronic lymphocytic leukemia (CLL)

ASCO 2019: Dr. Koffman’s Pick #6: Acalabrutinib with Obinutuzumab for chronic lymphocytic leukemia (CLL)

U.S. Food and Drug Administration (FDA) Approves Acalabrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)

Didn't find what you where looking for?

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT